Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against DoubleVerify Holdings, Inc. due to allegations of violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by July 21, 2025 [3][5]. Group 1: Allegations Against DoubleVerify - The complaint alleges that DoubleVerify misled investors by failing to disclose that customers were shifting ad spending to closed platforms, where the company's capabilities were limited [5]. - It is claimed that the development of technology for closed platforms was more expensive and time-consuming than disclosed, impacting the monetization of DoubleVerify's high-margin Activation Services [5]. - Competitors were reportedly better positioned to incorporate AI into their offerings, adversely affecting DoubleVerify's competitive stance and profitability [5]. - The company allegedly overbilled customers for ad impressions served to declared bots, and its risk disclosures were misleading, characterizing known adverse facts as mere possibilities [5]. Group 2: Impact of Disclosures - The truth about the alleged fraud was revealed through disclosures in February and March 2025, leading to a 36% drop in DoubleVerify's stock price following disappointing earnings and the suspension of services by a major customer [6]. - A report from Adalytics Research in March 2025 claimed that DoubleVerify's services were ineffective, further damaging investor confidence [6]. Group 3: Legal Proceedings - The lead plaintiff in the class action will be the investor with the largest financial interest who is typical of class members, and any member can move to serve as lead plaintiff or remain an absent class member [7]. - Faruqi & Faruqi encourages anyone with information regarding DoubleVerify's conduct to come forward, including whistleblowers and former employees [8].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In BigBear.ai To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in BigBear.ai between March 31, 2022 and March 25, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Far ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against West Pharmaceutical Services, Inc. due to allegations of misleading statements and failure to disclose significant operational issues that have negatively impacted the company's financial performance [2][4]. Group 1: Allegations Against West Pharmaceutical Services - The complaint alleges that West and its executives violated federal securities laws by making false and misleading statements regarding customer demand and operational challenges, particularly in their High-Value Products portfolio [4]. - Specific issues highlighted include the operational inefficiencies of the SmartDose device, which was expected to be a high-margin growth product but instead diluted profit margins [4]. - The allegations also mention the risk of costly restructuring activities, including the exit from continuous glucose monitoring contracts with long-standing customers, due to these margin pressures [4]. Group 2: Impact of Disclosures - The truth about the alleged fraud was revealed on February 13, 2025, when West issued weak revenue and earnings forecasts for 2025, attributing the disappointing guidance to contract manufacturing headwinds and the loss of two major customers [5]. - Following this announcement, West's stock price dropped by $123.17 per share, a decline of 38%, closing at $199.11 on the same day [5]. Group 3: Legal Proceedings - Investors who purchased securities in West between February 16, 2023, and February 12, 2025, are encouraged to discuss their legal rights and options, with a deadline of July 7, 2025, to seek the role of lead plaintiff in the federal securities class action [2][6]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought by the class, who will oversee the litigation on behalf of the class members [6].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Red Cat To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $75,000 in Red Cat between March 18, 2022 and January 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, June 4, 2025 /PRNewswire/ ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Elevance Health, Inc. due to alleged violations of federal securities laws, encouraging affected investors to come forward [2][4]. Group 1: Legal Investigation - The law firm is looking into claims against Elevance Health, reminding investors of the July 11, 2025 deadline to seek the role of lead plaintiff in a federal securities class action [2]. - The complaint alleges that Elevance and its executives made false or misleading statements regarding the monitoring of cost trends and the adequacy of premium rates for Medicaid programs [4]. Group 2: Financial Disclosures - On July 17, 2024, Elevance disclosed an expectation of increased utilization in Medicaid, leading to a stock price decline of $32.21 per share, or 5.8% [5]. - On October 17, 2024, Elevance reported third-quarter financial results, missing EPS expectations by $1.33, or 13.7%, and lowered its EPS guidance for 2024 from $37.20 to $33.00, or 11.3%, causing a further stock price decline of $52.61 per share, or 10.6% [6]. Group 3: Investor Participation - The lead plaintiff in the class action will be the investor with the largest financial interest who is typical of class members, and any member can move to serve as lead plaintiff or remain an absent class member [7]. - The firm encourages anyone with information regarding Elevance's conduct to contact them, including whistleblowers and former employees [8].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Iovance To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $100,000 in Iovance between May 9, 2024 and May 8, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, June 4, 2025 /PRNewswire/ -- Far ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Canopy Growth Corporation due to allegations of misleading statements and undisclosed costs that negatively impacted the company's financial performance [2][4]. Group 1: Allegations and Financial Impact - The complaint alleges that Canopy Growth and its executives violated federal securities laws by making false statements and failing to disclose significant costs related to the Claybourne product launch and Storz & Bickel vaporizer devices [4]. - Canopy reported a gross margin decrease of 400 basis points to 32% in Q3 2025, primarily due to costs associated with the Claybourne infused pre-roll launch and increased indirect costs related to vaporizer devices [5]. - The company experienced a wider-than-anticipated loss of C$1.11 per share in Q3 2025, compared to the C$0.48 per share loss estimated by analysts [5]. Group 2: Market Reaction - Following the announcement of the financial results, Canopy's share price fell by $0.76, or 27.34%, closing at $2.02 per share on February 7, 2025 [7]. Group 3: Legal Proceedings - Investors who purchased Canopy securities between May 30, 2024, and February 6, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights and the June 3, 2025, deadline to seek lead plaintiff status in the class action [2][8].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against DoubleVerify Holdings, Inc. due to allegations of misleading statements and failure to disclose critical information affecting investors [2][4]. Group 1: Allegations Against DoubleVerify - The complaint alleges that DoubleVerify's customers are shifting ad spending from open exchanges to closed platforms, where the company's technological capabilities are limited [4]. - It is claimed that DoubleVerify's ability to monetize its high-margin Activation Services is constrained due to the high costs and time required for technology development for closed platforms [4]. - The complaint states that DoubleVerify's competitors are better positioned to incorporate AI into their offerings, negatively impacting DoubleVerify's competitive edge and profitability [4]. - Allegations include that DoubleVerify systematically overbilled customers for ad impressions served to declared bots, and that risk disclosures were materially false and misleading [4]. Group 2: Impact of Disclosures - The truth about the alleged fraud was revealed through disclosures in February and March 2025, leading to a significant stock price drop of 36% following disappointing earnings [5]. - A report from Adalytics Research in March 2025 claimed that DoubleVerify's services were ineffective, further damaging investor confidence [5]. Group 3: Legal Proceedings - Investors who suffered losses in DoubleVerify are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options for participating in a federal securities class action [1][2]. - The deadline for seeking the role of lead plaintiff in the class action is set for July 21, 2025 [2].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Red Cat Holdings, Inc. due to allegations of misleading statements regarding the company's production capacity and contract values, which have led to significant stock price declines for investors [2][4][12]. Group 1: Allegations and Legal Actions - The complaint alleges that Red Cat and its executives violated federal securities laws by making false and misleading statements about the production capacity of the Salt Lake City Facility and the overall value of the SRR Contract [4][6]. - Investors who suffered losses from purchasing Red Cat securities between March 18, 2022, and January 15, 2025, are encouraged to discuss their legal rights with Faruqi & Faruqi [1][2]. - A federal securities class action has been filed against Red Cat, with a deadline of July 21, 2025, for investors to seek the role of lead plaintiff [2][14]. Group 2: Company Performance and Stock Impact - Red Cat's stock price fell by $0.10 per share (8.93%) to close at $1.02 on July 28, 2023, following disclosures about the actual production capacity of the Salt Lake City Facility being only 100 drones per month [8][7]. - On September 25, 2024, Red Cat's stock price dropped by $0.80 per share (25.32%) after the company reported losses per share of $0.17 and revenue of $2.8 million, missing consensus estimates [10][9]. - After Kerrisdale Capital published a report on January 16, 2025, alleging that the SRR Contract was worth only $20 million to $25 million, Red Cat's stock price fell by $2.35 per share (21.54%) to close at $8.56 on January 17, 2025 [12][13]. Group 3: Company Background and Initiatives - Red Cat was selected by the U.S. Department of Defense's Defense Innovation Unit to compete in the SRR Program, aimed at providing small, portable sUAS to U.S. Army platoons [5]. - The company has claimed that the SRR Contract could potentially generate hundreds of millions in revenue, with expectations of $50 million to $79.5 million in revenue during fiscal year 2025 [11].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against BigBear.ai Holdings, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading financial statements and accounting practices [2][4]. Group 1: Allegations and Financial Impact - The complaint alleges that BigBear maintained deficient accounting review policies, leading to incorrect determinations regarding the 2026 Convertible Notes and improper accounting practices [4]. - As a result of these errors, BigBear's financial statements since fiscal year 2021 are deemed unreliable and will require restatement, increasing the risk of delayed filings with the SEC [4][6]. - Following the announcement of the delayed filing of its 2024 10-K, BigBear's stock price fell approximately 15%, from $3.49 on March 17, 2025, to $2.97 on March 18, 2025 [5]. - After the filing of the restated 2024 10-K, the stock price declined further by about 9%, from $3.51 on March 25, 2025, to $3.19 on March 26, 2025 [7]. Group 2: Legal Proceedings and Investor Actions - Investors who suffered losses in BigBear.ai between March 31, 2022, and March 25, 2025, are encouraged to discuss their legal rights and options with Faruqi & Faruqi [1]. - There is a June 10, 2025, deadline for investors to seek the role of lead plaintiff in the federal securities class action against BigBear [2]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [8].